TheEdgeResearch
Home / Stocks / INKT

MiNK Therapeutics, Inc. (INKT)

NASDAQ Healthcare Biotechnology
$8.02 ▼ -6.85%
Market Cap
$41.2M
Sector
Healthcare
Industry
Biotechnology
Beta
0.45
52-Wk Range
7.756-16.93
CEO
Jennifer S. Buell
Country
US
Currency
USD

MiNK Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $8.02, down 6.85% on the session, giving a market capitalisation of $41.2M. On trailing twelve-month figures it carries a trailing P/E of -3.58, a net margin of -5512.5%. Its beta of 0.45 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-3.58
Price / Sales
205.86
Price / Book
0.00
EV / EBITDA
-2.90
Gross margin
26.6%
Operating margin
-6006.3%
Net margin
-5512.5%
Return on equity
—
Debt / equity
0.00
Current ratio
0.97
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
15
IPO date
2021-10-15
Headquarters
New York City, NY, US
About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.

Comparable companies

MiNK Therapeutics, Inc. is most often compared with the following Healthcare names:

CRVOEQGANXHOWLIOBTNRXPOSTXOTLKSPRBVTVT
More research on INKT
INKT technical analysis INKT TheEdge Score Compare against peers
Open full interactive analysis & DCF →